Skip to content

Sulindac

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Sulindac does in the body

Acute or long-term use in the relief of signs and symptoms of the following

From the FDA-approved label: Pharmacodynamics Sulindac tablets are a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. The mechanism of action, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition. Pharmacokinetics Absorption The extent of sulindac absorption from sulindac tablets is similar as compared to sulindac solution. There is no information regarding food effect on sulindac absorption.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · 184SNS8VUH · read 2026-08-29

  • Its recorded molecular formula is C20H17FO3S, weighing 356.42.

    US prescribing information · 1fffe88d-50c8-45cf-ac7c-a62b665c89a8 · read 2026-08-30

Where each sentence above came from

The recorded explanation names an amount, so it does not open this page. The page opens with what it is taken for instead, and the recorded explanation follows below.

Shown as the opening line on this page.

No statement of the main limit is recorded.

The four opening statements run to 98 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Protein

A protein is a folded chain your body builds to do a specific job.

A picture of it, and where the picture fails

A protein is like a tool bent into one shape for one task.

Where that stops being true. A tool keeps its shape. A protein can change shape and stop working.

What people get wrong. Protein in food and a protein in the body are related but not the same thing.

A polymer of amino acids folded into a defined structure that determines its function.

Enzyme

An enzyme is a protein that speeds up one chemical change.

A picture of it, and where the picture fails

An enzyme is like a machine on a production line doing one cut.

Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.

What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.

A catalytic protein that lowers the activation energy of a specific reaction.

Receptor

A receptor is a part of a cell that a signal fits into.

A picture of it, and where the picture fails

A receptor is like a lock waiting for one key.

Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.

What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.

A protein that binds a specific ligand and converts that binding into a cellular response.

Pathway

A pathway is a chain of steps inside a cell, each one setting off the next.

A picture of it, and where the picture fails

A pathway is like a row of dominoes.

Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.

What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.

An ordered series of molecular interactions producing a defined cellular change.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Periprosthetic joint infection

The study did not show it

Who was studied
NCT05164081
How many people
7000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

The study did not show it

Who was studied
NCT00085826
How many people
600
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Detection of Any Adenoma at the End of the Study

The study did not show it

Who was studied
NCT00118365
How many people
375
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC)

The study did not show it

Who was studied
NCT01349881
How many people
354
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Assess efficacy of drug vs placebo regarding overall rate of biochemical progression

The study did not show it

Who was studied
NCT00166426
How many people
240
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Number of Subjects With Any FAP-related Event.

The study did not show it

Who was studied
NCT01483144
How many people
171
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What happened in peopleRead from sources, not yet reviewed

How close this is to real life

The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.

  1. Living longer, or avoiding a major event No evidence recorded. Death, a heart attack, a stroke, a hospital stay.0 registered measures of this kind. 1 written-up study measured this and did not show a benefit.
  2. What a body can do day to day No evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
  3. Measured performance No evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
  4. Symptoms and quality of life No evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
  5. A number that stands in for health No evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.No registered study measures this.
  6. A step measured inside a person Evidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
  7. Animals Evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat. A result in animals says what to test next. It does not say what happens in people.
  8. Cells in a dish Evidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
  9. A guess from software No evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.

Higher on these steps means closer to something a person would feel. It does not mean better done.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac is indicated for acute or long-term use in the relief of signs and symptoms of the following: 1. Osteoarthritis 2. Rheumatoid arthritis 3.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “Pediatric Use Safety and effectiveness in pediatric patients have not been established.”

    US prescribing information · 1fffe88d-50c8-45cf-ac7c-a62b665c89a8 · read 2026-08-30

  • On older people, the label states: “As with any NSAID, caution should be exercised in treating the elderly (65 years and older) since advancing age appears to increase the possibility of adverse reactions.”

    US prescribing information · 1fffe88d-50c8-45cf-ac7c-a62b665c89a8 · read 2026-08-30

  • On people who are pregnant, the label states: “Fetal Toxicity Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs, including sulindac tablets, in pregnant women at about 30 weeks gestation and later.”

    US prescribing information · 1fffe88d-50c8-45cf-ac7c-a62b665c89a8 · read 2026-08-30

  • On people who are breastfeeding, the label states: “It is not known whether this drug is excreted in human milk; however, it is secreted in the milk of lactating rats.”

    US prescribing information · 1fffe88d-50c8-45cf-ac7c-a62b665c89a8 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied for a different goal

The studies measured something else entirely.

On this record: Some registered studies measured things that match no goal on this page.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S1, S4, S6.

No source is stored against this line.

What is in the pack

Sold as tablet, given by the oral route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Reports sent to a regulator

  • These are reports people sent to a regulator. They do not show the medicine caused the reaction.
  • Nobody counted how many people took the medicine and reported nothing.
  • The same event can be reported more than once, and many reports are incomplete.
  • News coverage, lawsuits and new warnings change how often people report.
  • A count is not a rate and not a risk.

Sulindac appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 170 reaction mentions were counted. One report can name several reactions.

The recorded terms (10)
  • drug hypersensitivity — 101 reaction mentions
  • gastrointestinal haemorrhage — 14 reaction mentions
  • gastric haemorrhage — 13 reaction mentions
  • haemoglobin decreased — 11 reaction mentions
  • stevens-johnson syndrome — 7 reaction mentions
  • hyperbilirubinaemia — 6 reaction mentions
  • gastric ulcer — 5 reaction mentions
  • toxic epidermal necrolysis — 5 reaction mentions
  • drug rash with eosinophilia and systemic symptoms — 4 reaction mentions
  • intestinal diaphragm disease — 4 reaction mentions
  • open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 21 products list this as an active ingredient in the United States drug directory. 21 of them contain it and nothing else.

    FDA National Drug Code directory · 42806-011 · read 2026-08-29

  • They are sold as powder and tablet, taken oral.

    FDA National Drug Code directory · 42806-011 · read 2026-08-29

  • The regulator's established pharmacologic class for it is anti-inflammatory agents, cyclooxygenase inhibitors [moa] and non-steroidal [cs].

    FDA National Drug Code directory · 42806-011 · read 2026-08-29

  • 10 published labels name it as an active ingredient. 10 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 1fffe88d-50c8-45cf-ac7c-a62b665c89a8 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 1fffe88d-50c8-45cf-ac7c-a62b665c89a8 · read 2026-08-29

  • SULINDAC is oral at HOW SUPPLIED Sulindac tablets USP are supplied as follows: Sulindac tablets, 200 mg, yellow, round, scored, debossed MP 116 Bottles of 100 NDC 72789-374-01 Bottles of 500 NDC 72789-374-82 Store at 20° to 25°C (68° to 77…, recorded as fda label in effect 2025-04-04 in the United States.

    US prescribing information · 1fffe88d-50c8-45cf-ac7c-a62b665c89a8 · read 2026-08-30

  • Recorded price in US: 0.18798–0.22697 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 12 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Sulindac studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Sulindac are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII)
184SNS8VUH
RxNorm concept
198239

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Written into the record, not signed off.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S1, S4, S6.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 13 approved applications cover products containing this substance. The earliest was NDA017911, approved 19780927 to MERCK.

    Drugs@FDA application register · NDA017911 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA017911 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19820101.

    FDA National Drug Code directory · 42806-011 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

8 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (11)

What did Sulindac's largest trial (375 people) and its longest (14 years) measure?


375 people in Sulindac's largest registered study, 14 years in its longest registered window, measuring Sulindac Concentration in the Nevi (Moles). ClinicalTrials.gov · 2026-09-01

15 phase2, 4 na, 2 phase3, 1 phase1; NCT00299195; 2020-01-06; no ageing endpoint recorded. Last human test completed 2020, NCT00299195.

Interpretation These counts include studies where Sulindac was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.

Show the evidence
  • phase2
    15
  • na
    4
  • phase3
    2
  • phase1
    1
  • Last recorded human test NCT00299195
    2020-01-06

recorded 2026-09-01 · last checked 2026-09-04

From mouse to human: where has Sulindac shown lifespan?


mouse: lifespan, rat: mechanism-only and human: biomarker (22): the rungs where Sulindac has a recorded finding. Europe PMC and ClinicalTrials.gov · organism ladder · 2026-09-01

Interpretation Sulindac Concentration in the Nevi (Moles) — the recorded outcome words.

Yeast C. elegans Drosophila Mouse lifespanRat mechanism-onlyDog Non-human primate Human biomarker
Show the evidence
  • mouse
    lifespan
  • rat
    mechanism-only
  • human NCT00841204
    biomarker; Sulindac Concentration in the Nevi (Moles); 22

recorded 2026-09-01 · last checked 2026-09-04

The NIA ITP gave Sulindac at 5 ppm from 5 months — did both sexes live longer?


5 ppm, from 5 months: the NIA Interventions Testing Program workbook rows for Sulindac. jax-mpd-itp · ITP_C2017_Lifespan.xlsx · 2026-09-04

292 mice; cohorts C2017; cohort rows are the workbook's own printed values; no median, percent change or survival statistic is derived from the per-animal data

Show the evidence
  • ITP cohort C2017
    sulindac; 5; 5.0 months; f, m; ITP_C2017_Lifespan.xlsx

recorded 2026-09-04 · last checked 2026-09-04

7 of Sulindac's trials stopped: accrual/recruitment, funding/business, sponsor decision unspecified, other?


accrual/recruitment (2), funding/business (2), sponsor decision unspecified (2) and other (1): Sulindac's stop wording, clustered. ClinicalTrials.gov · 2026-09-01

"Study completed"; 7 of 22 registered studies

Show the evidence

Trial

  • NCT00003365
    terminated; "Study completed"
  • NCT00062023
    terminated; "Study closed by the NCI."
  • NCT00176618
    terminated; "principal Investigator left institution"
  • NCT00392665
    terminated; "slow accrual"
  • NCT01636128
    withdrawn; "Funding and staffing"
  • NCT01843179
    withdrawn; "Lack of Funding"
  • 1 further recorded trial NCT01856322
    terminated; "The trial was prematurely closed due to lack of accrual."

recorded 2026-09-01 · last checked 2026-09-04

Mouse studies of Sulindac used 5 ppm — over how long?


studies of Sulindac used the recorded amount. clinicaltrials.gov+jax-mpd-itp · 2026-09-04

3 recorded entries; mouse, human; also "5 ppm", "Sulindac 150 MG", "Sulindac 400 MG"

Show the evidence
  • mouse sulindac C2017
    5 ppm

human

  • NCT01483144
    Sulindac 150 MG
  • NCT04207944
    Sulindac 400 MG

recorded 2026-09-04 · last checked 2026-09-04

Which of failure free at 2 years following study entry, pouch mucosal apoptosis index at 0 1 and 2 months and pouch mucosal proliferation index at 0 1 and 2 months did Sulindac's trials measure?


failure free at 2 years following study entry, pouch mucosal apoptosis index at 0 1 and 2 months and pouch mucosal proliferation index at 0 1 and 2 months lead 3 outcome terms across Sulindac's trials. ClinicalTrials.gov · 2026-09-01

3 terms in all.

Show the evidence
  • failure free at 2 years following study entry
    1
  • pouch mucosal proliferation index at 0 1 and 2 months
    1
  • pouch mucosal apoptosis index at 0 1 and 2 months
    1

recorded 2026-09-01 · last checked 2026-09-04

What will the one ongoing trial of Sulindac report, and when?


1 registered trial of Sulindac is open; earliest completion 2026-10-31. ClinicalTrials.gov · 2026-09-01

Interpretation Percent of patients with IPMN progression as measured by a composite of several indicators

Show the evidence
  • Trial NCT04207944
    "The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)"; n 100; "Percent of patients with IPMN progression as measured by a composite of several indicators"; 2026-10-31

recorded 2026-09-01 · last checked 2026-09-04

Which 4 trials of Sulindac posted no result?


Posted no result
4 of 4 completed trials
Registrations
NCT00343629, NCT00039520, NCT00245024 and NCT00755976
Completion dates
oldest 2007-10; newest 2010-05
Show the evidence

Trial

  • NCT00343629
    2007-10
  • NCT00039520
    2008-07
  • NCT00245024
    2010-01
  • NCT00755976
    2010-05

At the median, Sulindac's trials enrolled 50 people — anything larger?


Median enrolment
50
Largest enrolment
375
Registered trials counted
21

What do 170 spontaneous reports say about Sulindac — and not say?


These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Sulindac appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 170 reaction mentions were counted: drug hypersensitivity 101; gastrointestinal haemorrhage 14; gastric haemorrhage 13; haemoglobin decreased 11. open-targets-adr · CHEMBL15770 · 2026-06-24

Show the evidence
  • drug hypersensitivity
    101
  • gastrointestinal haemorrhage
    14
  • gastric haemorrhage
    13
  • haemoglobin decreased
    11
  • stevens-johnson syndrome
    7
  • hyperbilirubinaemia
    6
4 more recorded rows
  • gastric ulcer
    5
  • toxic epidermal necrolysis
    5
  • drug rash with eosinophilia and systemic symptoms
    4
  • intestinal diaphragm disease
    4

recorded 2026-06-24 · last checked 2026-09-04

What is recorded about Sulindac and NAD+?


"In this study, we have identified (E)-2'-des-methyl sulindac analogues as a novel class of STACs that act also in the absence of NAD<sup>+</sup>, a peculiar behavior demonstrated through enzymatic and mass spectrometry experiments, both in vitro and in cell lines." — where Sulindac and NAD+ appear together. Europe PMC · pathway abstract search · 2024-07-04

NAD+, autophagy, AMPK, sirtuin, mTOR; PMID 38971269, 37660128, 34472641, 27528025

Show the evidence
  • NAD+ PMID 38971269
    "In this study, we have identified (E)-2'-des-methyl sulindac analogues as a novel class of STACs that act also in the absence of NAD<sup>+</sup>, a peculiar behavior demonstrated through enzymatic and mass spectrometry experiments, both in vitro and in cell lines."
  • autophagy PMID 37660128
    "Further studies showed that sulindac binds to retinoid X receptor alpha (RXRα) and induces autophagy in GABAergic neurons, leading to activation of the mitochondrial apoptotic pathway."
  • AMPK PMID 34472641
    "Our results indicated that the combination of Sulindac and VD has a growth-inhibiting effect on MCF-7 cells through AMPK/Akt/β-catenin axis."
  • sirtuin PMID 27528025
    "Taken together, these results indicate that celecoxib and sulindac can inhibit TGF-β1-induced EMT and suppress lung cancer cell migration and invasion via downregulation of SIRT1."
  • mTOR PMID 27343825
    "Suppression of the Wnt pathway by sulindac relieved autistic-like behaviors and attenuated VPA-induced mTOR signaling activation in autistic model rats."

autophagy

  • PMID 23431290
    "Here, we show that inhibition of autophagy under serum-deprived conditions resulted in significant reductions of sulindac sulfide-induced apoptosis in HT-29 colon cancer cells."
  • PMID 23431290
    "In contrast, inhibition of autophagy under conditions where serum is available significantly increased sulindac sulfide-induced apoptosis in HT-29 cells."
  • mTOR PMID 23645590
    "Mechanistically, phospho-sulindac suppressed lung tumorigenesis by (i) inhibiting EGF receptor (EGFR) activation, leading to profound inhibition of Raf/MEK/ERK and PI3K/AKT/mTOR survival cascades; (ii) inducing oxidative stress, which provokes the collapse of mitochondrial membrane potential and mitochondria-dependent cell death; and (iii) inducing autophagic cell death."

NAD+

  • PMID 3375453
    "Cis- and trans-sulindac sulfide and cis- and trans-sulindac inhibit the NAD-linked enzyme as well or better than they inhibit various cyclooxygenases in vitro."
  • PMID 3375453
    "Cis- and trans-sulindac sulfide are sufficiently strong inhibitors of the NAD-linked enzyme (Kis of 7.8 microM and 6.8 microM respectively) to raise the possibility that they might also inhibit this enzyme in vivo."

recorded 2024-07-04 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL15770
PubChem CID
16046677
CAS number
190967-68-1
RxCUI
198239
InChIKey
MLKXDPUZXIRXEP-MFOYZWKCSA-N
Also called
SULINDAC [MART.], Arthrocine, Artribid, Sulindaco, 1H-INDENE-3-ACETIC ACID, 5-FLUORO-2-METHYL-1-((4-(METHYLSULFINYL)PHENYL)METHYLENE)-, (1Z)-, CIS-5-FLUORO-2-METHYL-1-((P-METHYLSULFINYL)BENZYLIDENE)INDENE-3-ACETIC ACID, SULINDAC [EP MONOGRAPH], SULINDAC [JAN], SULINDAC [MI]
Trade name
Clinoril, Flynpovi
Development code
MK-231, NSC-757344
Sources (11)

Sources

  • ClinicalTrials.gov ClinicalTrials.gov API v2 snapshot 2026-09-01T09:00:05 ·
  • clinicaltrials.gov+jax-mpd-itp clinicaltrials.gov+jax-mpd-itp ·
  • this record's own fields 2,3,5 ·
  • Europe PMC dose-response search ·
  • Europe PMC pathway abstract search ·
  • Europe PMC search ·
5 more sources

ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · NIA ITP via the JAX Mouse Phenome Database · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 11 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.